Stephen R.  La Neve net worth and biography

Stephen La Neve Biography and Net Worth

CEO of Accuray

Steve La Neve serves as Chief Executive Officer of Accuray, bringing over 40 years of global experience in medical technology and biotechnology, spanning capital equipment and implantable devices. He is recognized for driving operational excellence and delivering sustained value creation.

Prior to Accuray, Steve held several senior executive roles, including President of Globus Medical Japan K.K. and President of Globus Medical Trauma and Joint Reconstruction, a leading musculoskeletal technology company. He also served as Global Sector President for Medtronic’s Spine and Biologics Division. Across these roles, Steve consistently optimized operations, managed costs, achieved financial targets, and expanded revenue streams through innovative technology platforms.

Steve also served as CEO and Board Director of Bone Biologics Corporation, and as President & CEO of ETEX Corporation, where he led the successful sale of the business to a global leader in joint reconstruction. As Global President of Pre-Analytical Systems at Becton Dickinson, he drove revenue and profit growth that outpaced market performance.

Steve holds an MBA from West Chester University and a Bachelor of Science in Health Planning and Administration from Pennsylvania State University. He is a member of Omicron Delta Epsilon, an international honor society recognizing academic excellence and achievements in economics.

What is Stephen R. La Neve's net worth?

The estimated net worth of Stephen R. La Neve is at least $6.80 thousand as of November 19th, 2025. Mr. La Neve owns 20,000 shares of Accuray stock worth more than $6,800 as of September 28th. This net worth evaluation does not reflect any other investments that Mr. La Neve may own. Learn More about Stephen R. La Neve's net worth.

How do I contact Stephen R. La Neve?

The corporate mailing address for Mr. La Neve and other Accuray executives is 1240 Deming Way, Madison, WI, 53717. Accuray can also be reached via phone at (608) 824-2800 and via email at [email protected]. Learn More on Stephen R. La Neve's contact information.

Has Stephen R. La Neve been buying or selling shares of Accuray?

Stephen R. La Neve has not been actively trading shares of Accuray within the last three months. Most recently, on Wednesday, November 19th, Stephen R. La Neve bought 20,000 shares of Accuray stock. The stock was acquired at an average cost of $0.97 per share, with a total value of $19,400.00. Following the completion of the transaction, the chief executive officer now directly owns 20,000 shares of the company's stock, valued at $19,400. Learn More on Stephen R. La Neve's trading history.

Who are Accuray's active insiders?

Accuray's insider roster includes Jesse Chew (SVP), Brandon Green (CFO), Michael Hoge (VP), Stephen La Neve (CEO), Joshua Levine (CEO), Byron Scott (Director), Patrick Spine (SVP), Joseph Whitters (Director), and Suzanne Winter (President). Learn More on Accuray's active insiders.

Are insiders buying or selling shares of Accuray?

In the last year, Accuray insiders bought shares 1 times. They purchased a total of 20,000 shares worth more than $19,400.00. The most recent insider tranaction occured on November, 19th when CEO Stephen R. La Neve bought 20,000 shares worth more than $19,400.00. Insiders at Accuray own 2.4% of the company. Learn More about insider trades at Accuray.

Information on this page was last updated on 11/19/2025.

Stephen R. La Neve Insider Trading History at Accuray

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/19/2025Buy20,000$0.97$19,400.0020,000View SEC Filing Icon  
See Full Table

Stephen R. La Neve Buying and Selling Activity at Accuray

This chart shows Stephen R. La Neve's buying and selling at Accuray by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Accuray Company Overview

Accuray logo
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Read More

Today's Range

Now: $0.34
Low: $0.28
High: $0.38

50 Day Range

MA: $0.26
Low: $0.22
High: $0.33

2 Week Range

Now: $0.34
Low: $0.22
High: $2.10

Volume

361,081,905 shs

Average Volume

3,788,788 shs

Market Capitalization

$40.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39